Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...

Based on Catalent’s strong switching costs, we have the confidence to assign the company a narrow moat rating. Novo Holdings, the investment manager of the Novo Nordisk Foundation and ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...